LMR Partners’s Prime Medicine PRME Stock Holding History

LMR Partners’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,760	Closed	-$330K	–	1145
2022 Q4	$330K	Buy	+17,760	New	+$321K	0.01%	942

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LMR Partners's PRME Position: Q1 2023 in Review

LMR Partners sold out of Prime Medicine (PRME) in Q1 2023, closing a stake of 17,760 shares — an estimated $330K sold.

LMR Partners first reported a position in PRME in Q4 2022 and held it in 1 quarter. The position peaked at $330K in Q4 2022. 76 funds tracked by Wall St. Rank hold PRME as of Q1 2023.

LMR Partners reported no remaining Prime Medicine position as of Q1 2023 after selling out during the quarter.
LMR Partners sold 17,760 Prime Medicine shares in Q1 2023, an estimated $330K.
LMR Partners first reported a position in Prime Medicine in Q4 2022 and held it in 1 quarter.
LMR Partners's Prime Medicine position peaked at $330K in Q4 2022.
76 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.